News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Recipharm AB: Interim Report January – March 2014
May 12, 2014
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Regulatory News:
Recipharm AB (STO:RECI):
· Net sales amounted to SEK 578 million (517) an increase of 11,7 % (9,4% in constant FX-rates)
Help employers find you! Check out all the
jobs
and
post your resume
.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Deals
Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+
February 26, 2026
·
1 min read
·
Tristan Manalac
C-suite
Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home
February 25, 2026
·
2 min read
·
Annalee Armstrong
Weight loss
Novo Leans Into Oral Route With Weight Loss Partnership Worth up to $2.1B
February 25, 2026
·
2 min read
·
Tristan Manalac
Startups
Harbour Cofunds Cancer Startup, Hands Off Clinical-Stage Antibody
February 25, 2026
·
2 min read
·
Tristan Manalac